Fecal Calprotectin Measurement is a Marker of Short-Term Clinical Outcome and Presence of Mucosal Healing in Patients with Inflammatory Bowel Disease


A.Kostas, S.I. Siakavellas, et al. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World Journal of GastroenterologyNovember 2017. PMID: 29151692 DOI: 10.3748/wjg.v23.i41.7387.

Highlights from this Publication

“In our patient cohort, we were able to define an optimal cut-off FC value of 261 µg/g, which had a strong predictive value for the discrimination of future relapses vs maintenance of remission.”

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use.

Health Canada License: 80726

This citation describes applications that are outside of product claims (Intended use is: The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.)